vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $11.5M, roughly 1.3× TRANSACT TECHNOLOGIES INC). On growth, TRANSACT TECHNOLOGIES INC posted the faster year-over-year revenue change (11.9% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 3.5%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

IRIX vs TACT — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.3× larger
IRIX
$14.7M
$11.5M
TACT
Growing faster (revenue YoY)
TACT
TACT
+81.7% gap
TACT
11.9%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
3.5%
TACT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
TACT
TACT
Revenue
$14.7M
$11.5M
Net Profit
Gross Margin
37.2%
47.6%
Operating Margin
-10.1%
Net Margin
Revenue YoY
-69.7%
11.9%
Net Profit YoY
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
TACT
TACT
Q4 25
$14.7M
$11.5M
Q3 25
$12.5M
$13.2M
Q2 25
$13.6M
$13.8M
Q1 25
$11.9M
$13.1M
Q4 24
$12.7M
$10.2M
Q3 24
$11.6M
$10.9M
Q2 24
$12.6M
$11.6M
Q1 24
$11.8M
$10.7M
Net Profit
IRIX
IRIX
TACT
TACT
Q4 25
Q3 25
$-1.6M
$15.0K
Q2 25
$-994.0K
$-143.0K
Q1 25
$-1.7M
$19.0K
Q4 24
$-834.0K
Q3 24
$-1.9M
$-551.0K
Q2 24
$-2.7M
$-319.0K
Q1 24
$-3.5M
$-1.0M
Gross Margin
IRIX
IRIX
TACT
TACT
Q4 25
37.2%
47.6%
Q3 25
32.1%
49.8%
Q2 25
34.5%
48.2%
Q1 25
42.5%
48.7%
Q4 24
44.0%
44.2%
Q3 24
37.3%
48.1%
Q2 24
40.7%
52.7%
Q1 24
37.9%
52.6%
Operating Margin
IRIX
IRIX
TACT
TACT
Q4 25
-10.1%
Q3 25
-11.3%
0.1%
Q2 25
-6.9%
-1.9%
Q1 25
-1.7%
-0.1%
Q4 24
-3.9%
-10.3%
Q3 24
-16.1%
-7.7%
Q2 24
-20.9%
-3.8%
Q1 24
-28.0%
-12.2%
Net Margin
IRIX
IRIX
TACT
TACT
Q4 25
Q3 25
-12.6%
0.1%
Q2 25
-7.3%
-1.0%
Q1 25
-14.2%
0.1%
Q4 24
-6.6%
Q3 24
-16.7%
-5.1%
Q2 24
-21.2%
-2.8%
Q1 24
-29.5%
-9.7%
EPS (diluted)
IRIX
IRIX
TACT
TACT
Q4 25
$-0.11
Q3 25
$-0.09
$0.00
Q2 25
$-0.06
$-0.01
Q1 25
$-0.10
$0.00
Q4 24
$-0.05
$-0.80
Q3 24
$-0.12
$-0.06
Q2 24
$-0.16
$-0.03
Q1 24
$-0.21
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$6.0M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$31.1M
Total Assets
$29.2M
$44.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
TACT
TACT
Q4 25
$6.0M
$20.4M
Q3 25
$5.6M
$20.0M
Q2 25
$6.8M
$17.7M
Q1 25
$7.2M
$14.2M
Q4 24
$2.4M
$14.4M
Q3 24
$3.9M
$11.3M
Q2 24
$4.1M
$11.1M
Q1 24
$5.4M
$10.6M
Total Debt
IRIX
IRIX
TACT
TACT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
TACT
TACT
Q4 25
$31.1M
Q3 25
$4.7M
$31.8M
Q2 25
$6.1M
$31.3M
Q1 25
$852.0K
$30.9M
Q4 24
$2.1M
$30.6M
Q3 24
$2.6M
$38.4M
Q2 24
$4.2M
$38.5M
Q1 24
$6.5M
$38.6M
Total Assets
IRIX
IRIX
TACT
TACT
Q4 25
$29.2M
$44.8M
Q3 25
$28.4M
$45.0M
Q2 25
$31.6M
$44.5M
Q1 25
$34.2M
$44.2M
Q4 24
$29.1M
$44.0M
Q3 24
$30.2M
$50.5M
Q2 24
$31.2M
$50.4M
Q1 24
$34.1M
$51.9M
Debt / Equity
IRIX
IRIX
TACT
TACT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
TACT
TACT
Operating Cash FlowLast quarter
$609.0K
Free Cash FlowOCF − Capex
$589.0K
FCF MarginFCF / Revenue
5.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
TACT
TACT
Q4 25
$609.0K
Q3 25
$-1.2M
$3.6M
Q2 25
$-397.0K
$3.6M
Q1 25
$-1.1M
$-161.0K
Q4 24
$-1.2M
$2.4M
Q3 24
$-3.1M
$327.0K
Q2 24
$-1.3M
$636.0K
Q1 24
$-1.6M
$-1.5M
Free Cash Flow
IRIX
IRIX
TACT
TACT
Q4 25
$589.0K
Q3 25
$-1.2M
$3.6M
Q2 25
$-410.0K
$3.6M
Q1 25
$-1.2M
$-171.0K
Q4 24
$-1.2M
$2.4M
Q3 24
$-3.1M
$259.0K
Q2 24
$499.0K
Q1 24
$-1.7M
$-1.6M
FCF Margin
IRIX
IRIX
TACT
TACT
Q4 25
5.1%
Q3 25
-9.4%
27.1%
Q2 25
-3.0%
25.9%
Q1 25
-9.8%
-1.3%
Q4 24
-9.8%
23.2%
Q3 24
-26.5%
2.4%
Q2 24
4.3%
Q1 24
-14.0%
-14.9%
Capex Intensity
IRIX
IRIX
TACT
TACT
Q4 25
0.2%
Q3 25
0.1%
0.5%
Q2 25
0.1%
0.1%
Q1 25
0.1%
0.1%
Q4 24
0.1%
0.1%
Q3 24
0.0%
0.6%
Q2 24
0.0%
1.2%
Q1 24
0.0%
1.0%
Cash Conversion
IRIX
IRIX
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons